NCT04662671View on ClinicalTrials.gov

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

December 9, 2020

Study Completion Date

January 30, 2021

Conditions
COVID19
Interventions
DEVICE

RD-X19

Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.

Trial Locations (2)

33134

Site 2, Miami

77845

Site 1, College Station

All Listed Sponsors
lead

EmitBio Inc.

INDUSTRY

NCT04662671 - Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19 | Biotech Hunter | Biotech Hunter